New diagnostic tests help physicians predict HCV drug resistance
Hep C virus testing supports value of diagnostics in precision medicine.
Quest Diagnostics recently expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies.
Related: Predictions for the future of high-cost specialty drugs
These therapies include the recently FDA-approved Zepatier (Merck) and Daklinza (Bristol-Myers Squibb).
This will help enhance the ability of physicians to determine the type, dose or duration of treatment with direct acting antiviral agents (DAAs) therapies that inhibit the NS5A protein, which influences hepatitis C viral replication.
The use of diagnostic testing to guide clinicians to the most appropriate medication is an advance toward more personalized care, according to Mark Ginestro, a principal at KPMG Strategy who works with life sciences companies.
Ginestro
“We are starting to see that more drugs are being paired with companion diagnostics because they help focus the therapy on the right patients and also provide the manufacturer with a greater likelihood of approval and a more focused, less-costly trial,” Ginestro tells Managed Healthcare Executive. “The use of diagnostics in hepatitis C will allow the clinician to determine if the patient has more options on which drugs can be used.”
By using these diagnostics, payers will likely seek to create more price competition in populations where more options are applicable.
“Regardless of the use of these diagnostics, all the recently launched hepatitis C drugs are still expensive on a one-time basis,” Ginestro says. “However, given the 90+% curative rates, the high costs are still justified.”
Ginestro points out that it is important to note that the public references of significant price differences between the marketed HCV products are almost always comparing list prices. “List prices are rarely the ultimate price,” he explains. “Therefore, much of the public discussion of price comparison between the HCV products is not soundly based. While the drugs in the hepatitis C category are expensive and the prices generate a lot of headlines, it’s important not to overlook the value being delivered in terms of lower long-term overall treatment costs for millions of people carrying the virus.”
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
